Investors
Developing transformative therapies targeting cancer
Founded 20 years ago, Seattle Genetics was built on a foundation of scientific innovation, rigorous research and drug development practices, as well as a passion for helping patients. Our leadership in antibody-drug conjugates (ADCs) and focus on innovative, targeted therapies for cancer has resulted in an approved drug for multiple indications and a robust pipeline of innovative programs in clinical development for a range of hematologic and solid tumors.
02/16/19 9:03 pm EST
| (Common Stock)
High
Volume
Low
Mkt Cap
Copyright West LLC. Minimum 15 minutes delayed.